Healthcare - Articles

Caution: Your CV is your personal data. My advice as a recruiter, with many years experience in the clinical research industry, would be to take care where you send your CV and make sure your data is treated with the respect it deserves! The important thing is to be selective.
Recruitment websites can be confusing, strange places to the inexperienced.  If you are not sure, select an established agency with a name you recognise.  Follow the link to their website and find a contact name. Email or phone them to ask for advice. If the website doesn’t give you information about their recruiters, maybe it is best to give them a miss. Using the internet is supposed to be speedy and convenient.   However, a common complaint we hear is that sending off a CV to some recruitm…

Due to increasing interest and requests regrding the subject Pharmiweb have created a new Avian Flu resource page.
Pharmiweb are (within reason) pleased to announce the integration of an Avian Flu resource centre onto our main site. Due to the seriousness of the current situation and the global spread of the virus, we have had multiple requests for information and further reading regarding the subject. Avid readers will have access to all the latest information and news regarding the migration of the virus and its effects on the consumer, the Pharma industry and how governments are planning to tackle this potential crisis. In addition to frequently updated news you will find related features, press releases, and useful resource links. Take a browse and let us know what you think! http:…

Due to demand, we at PharmiWeb have added a new Executive Jobs Listing to our comprehensive careers section. All these jobs include packages of over £100K (GBP) per year.
We are pleased to announce that, due to demand, we have added a new section to the site. Executives in the Pharmaceutical industry can now find the best selection of jobs with packages of £100K+ (GBP) per year. These executive pharma jobs are automatically taken from our extensive database of over 4800 live jobs, provided by our partners in Agencies and PharmaCos across the industry. This means that the listing will be constantly updated with new jobs as soon as they are posted. Visit our new Executive Jobs page here.

For those new to the industry, a quick round up of the common abbreviations and what they stand for might be useful....
ABPI Association of British Pharmaceutical Industry ADME Absorption, Distribution, Metabolism and Excretion ADR Adverse Drug Reaction AE Adverse Event CPMP Committee for Proprietary Medicinal Products CRF Case Report Form CSM Committee on Safety of Medicines CTC Clinical Trial Certificate CTX Clinical Trial Certificate of Exemption DBDD Double Blind Double Dummy EMEA European Medicines Evaluation Agency FDA Food and Drug Administration GCP Good Clinical Practice GMP Good Manufacturing Practice IDB Investigators’ Drug Brochure IEC Independent Research Ethics Committee MAA Marketing Authorisation Approval MHRA Medicines and Healthcare Produ…

Complete our user survey and you could win a £25 Amazon voucher!
Yes, take part in the PharmiWeb.com Autumn survey and your name will go into the hat for our monthly prize draw. Simply answer a few question and give us some of your valuable feedback, and each month we'll pull a name out of the hat for a £25 Amazon Voucher. It will only take a couple of minutes to complete, so what are you waiting for... Complete the survey

The prevalence of diabetes, in particular type 2 diabetes, is increasing worldwide. Type 2 diabetes increases with age, but recently has been affecting much younger individuals. In the UK, diabetes prevalence has doubled over the last 12-15 years, and is set to double again over a similar timeframe. The prevalence of diabetes in the UK is now, on average, 3.3%, though many patients are undiagnosed.
The prevalence of diabetes, in particular type 2 diabetes, is increasing worldwide. Type 2 diabetes increases with age, but recently has been affecting much younger individuals. In the UK, diabetes prevalence has doubled over the last 12–15 years, and is set to double again over a similar timeframe. The prevalence of diabetes in the UK is now, on average, 3.3%, though many patients are undiagnose…

Bristol-Myers Squibb was named today as one of the 10 Best Companies for Working Mothers by Working Mother magazine. This is the eighth consecutive year that the company has been listed in the ranking of the 100 Best Companies, and the fifth year in a row Bristol-Myers Squibb has been named a Top 10 company.
Bristol-Myers Squibb Named  one Of The 10 Best Companies For Working Mothers Celebrates Fifth Consecutive Year on "Top 10" List NEW YORK, NEW YORK (September 12, 2005) - Bristol-Myers Squibb was named today as one of the 10 Best Companies for Working Mothers by Working Mother magazine. This is the eighth consecutive year that the company has been listed in the ranking of the 100 Best Companies, and the fifth year in a row Bristol-Myers Squibb has been named a Top 10 company. Bel…

On Wednesday 22nd June, PharmiWeb Solutions and Microsoft brought together a senior group of sales and marketing professionals, to discuss how software and e-business based solutions can deliver competitive advantage for the pharmaceutical organisation.
On Wednesday 22nd June, PharmiWeb Solutions and Microsoft brought together a senior group of sales and marketing professionals, to discuss how software and e-business based solutions can deliver competitive advantage for the pharmaceutical organisation.   “In planning for this event, we were keen to avoid the usual traps of either speaking techno-babble, or failing to focus on business issues, and so I hope with our range of speakers that we were able to draw attention to how the practical application of technology-based solutions can…

Pharma Sales World 2005 will provide delegates with a unique opportunity to gain critical business information about how Europe’s leading pharma companies are addressing the challenge of improving sales force effectiveness. The conference will highlight the issues of accessibility, emerging customer bases, market changes in the next decade, sales force size and structure, targeting and segmentation, the new breed of representative, data acquisition, training and development, customer relationshi
Never before has the industry been positioned for such dramatic change as what the pharmaceutical sector is currently facing, creating more uncertainty in an already challenging market. At Pharma Sales World 2005 we have an exceptional programme that will provide creative solutions for the toughe…

Fractures resulting from osteoporosis are widely recognised as a major cause of morbidity and mortality in the elderly population. It has been estimated that approximately 310,000 osteoporotic fractures occur annually in the UK, with a consequent cost to the health service of £1.7 billion.
Fractures resulting from osteoporosis are widely recognised as a major cause of morbidity and mortality in the elderly population. It has been estimated that approximately 310,000 osteoporotic fractures occur annually in the UK, with a consequent cost to the health service of £1.7 billion. Over the past two decades major advances have been made in the management of this disease and a number of pharmacological agents have been approved for the reduction of fracture risk in postmenopausal women with osteopo…

On Friday 16th September, before a glittering audience of local business Champions, Exco was awarded the highly acclaimed prize of Small Business of the Year 2005.
  The Small Business of the Year Award was presented in recognition of Exco’s successful implementation of a strategic business development plan, leading to growth within an increasingly competitive environment. The judges were unanimous in their statement confirming that Exco is ‘Truly Entrepreneurial, this Company is committed to achieving Best Practice in every aspect of its Business’.  The organization has benefited from a strategic approach where objectives are outlined and all staff are encouraged to participate in driving the business forward. This has lead to continued success across every division, a steady gro…

Any nurse can start a business, including two-year graduates and diploma nurses. No advance degrees are necessary unless your business includes diagnosing and treating medical problems. State nurse practice acts do no prohibit a nurse from starting up their own business as an Independent Nurse Contractor.
Career Options For The Ambitious Nurse Entrepreneur Nurses are taking control of their careers by exploring options other than the traditional roles of yesteryear. Independent RN Contractors are storming the healthcare field. There was a time when nurses were hesitant about cutting the ties from the employer not true today. More and more nurses are now enjoying the many benefits of self-employment. Nurse Contractors are now a large part of the nursing industry thanks to the ambitious n…

Epilepsy is characterised by a tendency to experience unprovoked seizures and is one of the most common neurological disorders. Over 2% of the population will experience a seizure at some time in their life, and recurrent unprovoked seizures will require treatment in approximately one-in-200 people at any given time. Treatment of epilepsy remains important in helping to reduce the psychological and social sequelae which follow on from uncontrolled seizures.
Epilepsy is characterised by a tendency to experience unprovoked seizures and is one of the most common neurological disorders. Over 2% of the population will experience a seizure at some time in their life, and recurrent unprovoked seizures will require treatment in approximately one-in-200 people at any given time. Treatment of epileps…

It is often forgotten that until the late 1950s there was no treatment for schizophrenia, or for that matter, any other severe enduring mental illness. The majority of patients admitted to asylum care never left: hence the peak occupancy of 150,000 reported in the UK in 1955. As an interesting comparison, this is twice the current UK prison population.
It is often forgotten that until the late 1950s there was no treatment for schizophrenia, or for that matter, any other severe enduring mental illness. The majority of patients admitted to asylum care never left: hence the peak occupancy of 150,000 reported in the UK in 1955. As an interesting comparison, this is twice the current UK prison population. The discovery of conventional (or typical) antipsychotic drugs made a major contribution…

According to LeadDiscovery's recent feature report, Pain Therapeutics 2005, about one and a half billion people suffer from moderate to severe chronic pain worldwide, driving the market for analgesics to nearly $23 billion in 2004. Many companies are investing heavily in the development of new pain therapeutics, even more so now with the recent problems to have hit the Cox-II inhibitors. Calcium channel blockers stepped into the spotlight at the end of last year with the FDA approval of Elan's Z
According to LeadDiscovery's recent feature report, Pain Therapeutics 2005, about one and a half billion people suffer from moderate to severe chronic pain worldwide. The value of the pharmaceutical market for pain relief reflects this seeming worldwide epidemic of pain, with the overall value reach…

Worth an estimated $35 billion in 2003, analysts predict that the sale of oncology therapeutics will grow to $60 billion by 2010. Targeted therapeutics represent one of the most exciting new developments in the field of oncology and include angiogenesis inhibitors; apoptosis stimulators and; signal transduction inhibitors. Apoptosis stimulators lead by Genta's Genesense are particularly appealing. Canadian researchers are focusing on a stimulator of apoptosis known as pancratistatin. This molecu
Oncology is the third largest pharmaceutical market, behind the cardiovascular and CNS therapy areas, and is currently experiencing strong growth. Worth an estimated $35 billion in 2003, analysts predict that the sector will grow to $60 billion by 2010, yielding a compound annual growth rate of 8%…

Parkinson's disease drug revenues grew an impressive 17% across the seven major markets to reach $1.7 billion in 2003. Despite the commercial success associated with this therapy area, currently available treatments focus on levodopa which replaces the loss of striatal dopamine, the hall mark of Parkinson's disease, rather than targeting disease progression. The efficacy of levodopa eventually declines in most patients and new therapies with disease modifying activity are urgently required. A gr
Parkinson's disease is a chronic and progressive neurological condition that affects approximately 1.5 million people in the US alone. While its cause is unknown, the symptoms of Parkinson's disease are primarily the result of degeneration of dopaminergic neurons, in the substantia nigra, a part of…

Hypertension continues to represent a highly prevalent clinical problem affecting 190 million people in the 7 major pharmaceutical markets. This therapeutic area is also a highly lucrative field for pharmaceutical companies with sales exceeding $30 billion in 2003. Despite the improved efficacy and tolerability of the angiotensin receptor blocker class led by valsartan, physicians remain frustrated by the lack of efficacy of antihypertensive agents and the current trend is towards the use of com
Hypertension is defined as a systolic blood pressure of >139mmHg or a diastolic blood pressure of >89mm. Once these values increase past 160 and 100 respectively patients are classified as having stage 2 disease. Although there is a growing awareness of cardiovascular risk factors and the n…

Earlier in 2005, LeadDiscovery published an in depth report on the development of the novel anti-cancer class, the HDAC inhibitors. As this class advances with therapeutic candidates now entering phase II trials, companies are seeking to optimize therapeutic margins by targeting specific isoforms of histone deacetylase that are involved in tumor progression. In a recent NEJM study Prof. Peter Barnes and colleagues demonstrates that the inhibition of HDAC2 could introduce airway risks, possibly e
Earlier in 2005, LeadDiscovery published an in depth report on the development of the novel anti-cancer class, the HDAC inhibitors (see Histone deacetylase inhibitors-Moving from the bench to a promising companion for classic and targeted cancer therapies). This report, in addition to discussing the…

The overlapping fields of angiogenesis and growth factor biology represent two extensively investigated areas of modern day oncology and the recent success of Avastin, a monoclonal antibody that binds to and neutralizes one such growth factor, VEGF has not only resulted in the introduction of an effective clinical tool for the treatment of cancer but it also helped spark a wave of optimism in the angiogenesis inhibitor arena. As a result companies are evaluating new approaches to target VEGF in
The overlapping fields of angiogenesis and growth factor biology represent two extensively investigated areas of modern day oncology (see Innovative Cancer Therapies: Targeted therapy, a clinical and commercial revolution) and the recent success of Avastin, a monoclonal antibody that binds to and ne…